Clinical Trials
20 trialsNCT03902184 2026-04-29
TELLOMAK
Innate Pharma
Phase 2 Completed
NCT06854653 2026-04-29
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
NCT06534060 2025-10-03
MB-105 in Patients With CD5 Positive T-cell Lymphoma
March Biosciences Inc
Phase 2 Recruiting
NCT03628612 2025-08-07
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Autolus Limited
Phase 2 Enrolling by invitation
NCT03372057 2025-03-07
PRIMO
SecuraBio
Phase 2 Completed
NCT03493451 2024-10-26
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
BeiGene
Phase 2 Completed
NCT00893516 2024-04-09
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
Emergent BioSolutions
Phase 2 Terminated
NCT03713320 2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT03837457 2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT00542919 2020-10-19
A Study for Patients With Non-Hodgkin's Lymphomas
Eli Lilly and Company
Phase 2 Completed
NCT00426764 2020-02-11
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Celgene
Phase 2 Completed
NCT00364923 2019-12-19
PROPEL
Acrotech Biopharma Inc.
Phase 2 Completed
NCT00655668 2019-11-25
EXPECT
Celgene
Phase 2 Terminated
NCT00807495 2018-03-27
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Takeda
Phase 2 Completed
NCT00611208 2016-11-29
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
Virogen Biotechnology Inc.
Phase 2 Completed
NCT01421667 2016-11-28
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Seagen Inc.
Phase 2 Completed
NCT01486277 2016-11-03
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT00798096 2016-09-19
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Rigel Pharmaceuticals
Phase 2 Completed
NCT00421213 2012-07-19
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers
Alaunos Therapeutics
Phase 2 Completed
NCT00043368 2009-03-12
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Pfizer
Phase 2 Completed